After injury-plagued season, Texas Collin Johnson hopes to go out with a bang in the Alamo Bowl – San Antonio Express-News

It was the cruelest bit of irony for the Longhorn brothers.

There was fifth-year tailback Kirk Johnson, an injury magnet with the worst of luck, on the field against West Virginia flashing the zip and power he once displayed as a prep prospect. On the sideline was wideout and younger sibling Collin Johnson, unable to play because of a nagging hamstring injury that derailed his senior season.

Kirks presence in the backfield with Collin split out wide was a moment the two had envisioned for years. It was a dream they clung to as Kirk underwent all manner of surgeries and treatments and injections to return to the field.

Fate had other plans in store, and a seasons worth of injury woes provided the younger Johnson with a fresh perspective.

I put my arm around him one time and was like, Kirk, I know exactly how you feel now, Collin said Sunday. Except his was probably 10 times worse because he had to deal with that for years and years. Definitely my respect for Kirk grew, which I didnt think was possible, but I had a taste of what he was dealing with.

On ExpressNews.com: Longhorns defense refocused after losing leader

Collin deemed this final season in burnt orange beyond frustrating.

He first suffered a hamstring injury in the third quarter of the season opener against Louisiana Tech, and it grew more severe than he anticipated. That began a miserable cycle in which he missed six of 10 games despite undergoing treatment that included several platelet-rich plasma (PRP) injections.

I barely practiced before LSU (in Week 2), got a lot of treatment on it and tried to play in that game, Collin said. After that game, my hamstring was pretty bad so I had to sit out, get a shot, try to play, get hurt again, got another shot. Its been a chaotic situation.

Collins story at Texas couldve ended in January at the Superdome.

He considered declaring for 2019 NFL draft recording a career-high 68 receptions for 985 yards and seven touchdowns. Plus, turning pro after hoisting the Sugar Bowl trophy wouldve been a legendary exit.

But there were still gains to be made, a Big 12 championship to be delivered, a chance to play alongside Kirk one final time. Collin couldnt deliver on many of the goals he outlined, though there are no regrets on returning for one more year.

At the end of the day, Im human, and I have those thoughts, like what if this, what if that, Collin admitted. But I wouldnt change a thing.

I know things didnt go anywhere near where I wanted to on a personal level. Even as a team this year, its been a little frustrating for me. But at the end of the day, you have to make a decision and roll with it, and I learned a lot from it.

When healthy, Collin was still every bit the imposing 6-foot-6 matchup nightmare hes always been.

During a four-game stretch midway through the season, the only extended period he was near full health, Collin averaged seven receptions and 97.3 yards. His presence alongside senior slot maven Devin Duvernay can elevate the Longhorns offense from dangerous to downright deadly, and junior quarterback Sam Ehlinger is thrilled he gets one more outing with the pair.

Having Collin obviously is a huge help for us because of the player that he is as well as the connection that we have together, Ehlinger said Sunday. Through my college career, hes been the one guy who I consistently connected with.

Im very comfortable with him out on the field. He poses an issue because now teams arent going to be able to double Devin and double Collin. They have to pick one or the other.

On ExpressNews.com: Receivers Collin Johnson, Devin Duvernay form Longhorns most dynamic duo

Its possible a long, fruitful NFL career awaits Collin. He looms as an intriguing vertical option and massive mismatch in the end zone against defenders who might be half a foot shorter.

Rather than playing it safe and sitting out as some draft-worthy seniors do, Collin is eager to run with his brothers in burnt orange in last time. He could make a case as an early round pick with an explosive outing against 11th-ranked Utah and its stout pass defense.

And while it isnt the finale Collin hoped for, he can go out on a high note by leading Texas to three straight bowl wins for the first time since it won five in a row last decade (2004-08).

Its always hard to put a percentage on a hamstring because its one of those lingering injuries, but I feel great, Collin said. People can argue its a bowl game, things like that, and a lot of people choose to sit out for whatever reason. But for me, I just get another opportunity to go out there and play the game I love, so it just comes down to that.

nmoyle@express-news.net

Twitter: @NRMoyle

See original here:
After injury-plagued season, Texas Collin Johnson hopes to go out with a bang in the Alamo Bowl - San Antonio Express-News

Gene Therapies Make it to Clinical Trials – Discover Magazine

After years of ethical debates and breakthroughs in the lab, CRISPR has finally made its way to clinical trials. Researchers are now looking at whether the DNA-editing tool, as well as more conventional gene therapies, can effectively treat a wide array of heritable disorders and even cancers.

Theres been a convergence of the science getting better, the manufacturing getting much better, and money being available for these kinds of studies, says Cynthia Dunbar, a senior investigator at the National Heart, Lung, and Blood Institute. Its truly come of age.

CRISPR formally known as CRISPR-Cas9 has been touted as an improvement over conventional gene therapy because of its potential precision. CRISPR (clustered regularly interspaced short palindromic repeats) is a genetic code that, contained in a strand of RNA and paired with the enzyme Cas9, acts like molecular scissors that can target and snip out specific genes. Add a template for a healthy gene, and CRISPRs cut can allow the cell to replace a defective gene with a healthy one.

In April, scientists at the University of Pennsylvania announced they had begun using CRISPR for cancer treatments. The first two patients one with multiple myeloma, the other with sarcoma had cells from their immune systems removed. Researchers used CRISPR to genetically edit the cells in the lab, and then returned them back into their bodies.

On the other side of the country, Mark Walters, a blood and bone marrow transplant specialist at the University of California, San Francisco, Benioff Childrens Hospital in Oakland, is gearing up for trials that will use CRISPR to repair the defective gene that causes sickle cell disease. With CRISPR, once youve made that type of correction, [that cell] is 100 percent healthy, says Walters.

Another team is tackling the same disease using a type of hemoglobin, a protein in red blood cells, thats normally made only in fetuses and newborn babies. Researchers found that some adults continue to produce these proteins throughout their lives, and when those adults also have sickle cell disease, their symptoms are mild. So the international team used CRISPR to disable the gene that interferes with production of this hemoglobin, resuming its production and protecting the adult patients against sickle cell disease.

Several other CRISPR studies are in the works to treat a range of inherited disorders, including hemophilia and SCID-X1 (also known as X-linked severe combined immunodeficiency, the so-called bubble boy disease in which babies are born without a functioning immune system).

At St. Jude Childrens Research Hospital, a gene therapy trial cured Gael Jesus Pino Alva (pictured with his mother, Giannina) of SCID-X1, the bubble boy disease. (Credit: St. Jude Children's Research Hospital/Peter Barta)

The past year also saw success in a handful of experiments on conventional gene therapy. Instead of using CRISPR to repair disease-causing genes, these treatments use hollowed-out viruses to ferry healthy versions of genes into cells. Millions of these altered cells are released into the bloodstream or bone marrow in hopes that enough will land in the right places. But because scientists cant predict where the circulating genes may end up, this shotgun approach has had unintended, sometimes fatal, consequences including, in an earlier study, inadvertently activating leukemia-causing genes in patients treated for SCID-X1.

But in 2019, researchers learned that using a different type of virus one related to HIV to transport the genes may prevent these side effects. In an April study, researchers at St. Jude Childrens Research Hospital in Memphis, Tennessee, and UCSF Benioff Childrens Hospital in Oakland collected bone marrow from eight newborns with SCID-X1. They loaded corrective genes into the disabled HIV-related virus, which carried them into the patients bone marrow stem cells. The infants also received low doses of busulfan, a chemotherapy that gave the doctored stem cells room to grow. So far, we havent seen anything worrisome, says Ewelina Mamcarz, a pediatric oncologist at St. Jude who led the research team. The study recently added its 12th patient.

Gene therapy does have its momentum [back], says Mamcarz, reflecting on the fields setback after the earlier studys leukemia side effects. Theres so much that still needs to be done, and so many questions, she says. [But] this is how medicine evolves. We always want to be better than we were a week ago.

In the future, the hope is that gene therapy technologies will move beyond mending simple genetic mistakes and be used to combat big killers like diabetes or heart disease. [Those diseases are] more challenging, but a lot of them would benefit from knocking out a bad gene, says Dunbar.

For now, though, researchers are optimistic about the progress thats already been made. All of this has been very encouraging, says Dunbar. [And] for sickle cell in the U.S. and hemophilia in the developed world, these diseases may soon be solved.

[This story originally appeared in print as "Gene Therapy Gets Clinical."]

Original post:
Gene Therapies Make it to Clinical Trials - Discover Magazine

Stem Cells Market- What Are The Main Factors That Contributing Towards Industry Growth? – Industry Mirror

Stem Cells Market AnalysisAccording to Market Research, the Global Stem Cells Market was valued at USD 5.88 Billion in 2018 and is expected to witness a growth of 10.32% from 2019-2026 and reach USD 12.96 Billion by 2026.

What is Stem Cells Market?Stem cellscan be defined as unspecialized cells that develop into the specialized cells and make up different types of tissue in the human body. Since stem cells are unspecialized type of cells and are capable of renewing themselves through cell division. Stem cells can be Pluripotent as well as Multipotent.

Pluripotent stem cells are stem cells usually found in embryos which give rise to all the cells found in the human body, while multipotent stem cells, which are found in adults or in babies umbilical cords, have a more restricted ability. Their development is limited to cells that form the organ system that they are originated from. When a stem cell undergoes division, each new cell possess a potential either to remain a stem cell or develop into another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

Request For Full Report:https://www.kennethresearch.com/sample-request-10085010

Stem Cells Market OutlookStem cell research is considered as one of the most intriguing areas of contemporary biology, but, as with many expanding fields of scientific inquiry, research on stem cells stimulates scientific queries as rapidly as it produces new discoveries. Until recently, scientists used to primarily work with two types of stem cells from animals and humans: embryonic stem cells and non-embryonic somatic or adult stem cells.

Since the advent of stem cells, one of the crucial benefits of stem cell research is the accessibility of cell lines and that they can be acquired ethically. The demands for pluripotent stem cells are increasing owing to the fact that it differentiates in various cell types in the human body. Pluripotent stem cells tend to have various applications in the medical treatment. Growing awareness regarding the stem cells and establishment of stem cell banks is expected to fuel the market growth rate.

Request To Download Sample of This Strategic Report >>https://www.kennethresearch.com/sample-request-10085010

Ethical issues related to pluripotent stem cells could hamper the growth of stems cells in the global market as research with these cells require disrupting an artificially-fertilized embryo at the 5-14 day stage. Another factor which is limiting the growth of stem cells market is unknown long-term consequences.

Global Stem Cells Market SegmentationThe Global Stem Cells Market is classified on the basis of Product, Treatment Type, Therapeutic Application and Region. The gist of breaking down the market into various segments is to gather the information about various aspects of the market.

On the basis of Products, the market is bifurcated on the basis of Adult Stem Cells, Human Embryonic Cells, and Induced Pluripotent Stem Cell. Adult stem cells accounts for a major share in the global stem cells market. Even though embryonic stem cells have a wide range of applications, the market growth rate for this sub-segment is substantial owing to the ethical issues faced by this sub-segment in the global market.

In terms of Therapeutic Application, the market study encompasses various aspects such ca Regenerative Medicine, Neurological Disorders, Orthopedic Treatments, Oncology Disorders, Diabetes, Injuries & Wounds and Cardiovascular Disorders. Growing awareness regarding regenerative medicine is expected to make this sub-segment hold a potential market share globally. Growing healthcare expenditure and presence of major industry players makes North America hold major share in the global market.

Stem Cells Market Competitive LandscapeThe Stem Cells Market study report offers a valuable insight with an emphasis on global market including some of the major players such asBioTime Inc., Cytori Therapeutics, Inc., STEMCELL Technologies Inc., Astellas Pharma Inc., U.S. Stem Cell, Inc., Osiris Therapeutics, Inc., Takara Bio Inc., Caladrius Biosciences, Inc., Cellular Engineering Technologies Inc., and BrainStorm Cell Therapeutics Inc. Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above mentioned players globally.

View Source Of Related Reports:

Stem Cells MarketCar Rental MarketThermoelectric Modules MarketCar Audio MarketQuantum Computing MarketInternet of Things (IoT) MarketIndustrial Cybersecurity Market

Analyst View:As per our sources following trends were observed in terms of most popular sources of stem cells:

Stem cells from adult bone marrow were observed to be the most popular source. Scope of stem cell therapy is increasing with growing number of applications. Clinical research has advanced to a great magnitude towards preventing, identifying and handling devastating diseases. Various applications of stem cells in regeneration such as Cardiac Regeneration, Hepatic Regeneration, Regeneration of Neural Tissue, etc. have come up lately. This suggests that the market for stem cells will grow significantly over the forecast period.

Research Methodology of Verified Market Research:

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our sales team at Verified Market Research.

Request For Full Report:https://www.kennethresearch.com/sample-request-10085010

Reasons to Purchase this Report

Download Samples of this Strategic Report according to region wise: >>>https://www.kennethresearch.com/sample-request-10085010

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products demand, growth and opportunities for new and existing players.

Contact Us

Kenneth ResearchEmail:[emailprotected]Phone: +1 313 462 0609

This post was originally published on Industry Mirror

View post:
Stem Cells Market- What Are The Main Factors That Contributing Towards Industry Growth? - Industry Mirror

Stem Cell Therapy for Osteoarthritis Market Report by Manufacturers, Regions, Type and Application Forecast 2019 2025 – Info Street Wire

Stem Cell Therapy for Osteoarthritis Market primary data collection was achieved by interviewing the retailers and the consumers. The interviews were conducted through one to one structured questionnaire supervision.

Global Stem Cell Therapy for Osteoarthritis Market report provides an in-depth analysis of all market dynamics including drivers and restraints, and trends and opportunities. Important factors supporting growth across various is also provided. Using the industrial figures, the market finds growth figures between the forecast timespan.

Request Exclusive Free Sample PDF Of This Report At https://dataintelo.com/request-sample/?reportId=80747

In order to present an executive-level model of the market and its future perspectives, Stem Cell Therapy for Osteoarthritis Market report presents a clear segmentation based on different parameters. The factors that affect these segments are also discussed in detail in the report.

Major Players included in this report are as follows MesoblastRegeneusU.S. Stem CellAnterogenAsterias Biotherapeutics

To purchase this report, Visit https://dataintelo.com/checkout/?reportId=80747

Stem Cell Therapy for Osteoarthritis Market can be segmented into Product Types as MonotherapyCombination Therapy

Stem Cell Therapy for Osteoarthritis Market can be segmented into Applications as Osteoarthritis (unspecified)Knee OsteoarthritisShoulder OsteoarthritisHip Osteoarthritis

Stem Cell Therapy for Osteoarthritis Market: Regional analysis includes:Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)Europe (Turkey, Germany, Russia UK, Italy, France, etc.)North America (United States, Mexico, and Canada.)South America (Brazil etc.)The Middle East and Africa (GCC Countries and Egypt.)

For More Information on this report, Request Inquiry At https://dataintelo.com/enquiry-before-buying/?reportId=80747

The research provides answers to the following key questions: What is the global (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) production, production value, consumption, consumption value, import and export of Stem Cell Therapy for Osteoarthritis? Who are the global key manufacturers of Stem Cell Therapy for Osteoarthritis industry? How are their operating situation (capacity, production, price, cost, gross and revenue)? What are the types and applications of Stem Cell Therapy for Osteoarthritis? What is the market share of each type and application? What are the upstream raw materials and manufacturing equipment of Stem Cell Therapy for Osteoarthritis? What is the manufacturing process of Stem Cell Therapy for Osteoarthritis? Economic impact on Stem Cell Therapy for Osteoarthritis industry and development trend of Stem Cell Therapy for Osteoarthritis industry. What will the Stem Cell Therapy for Osteoarthritis Market size and the growth rate be in 2025? What are the key factors driving the global Stem Cell Therapy for Osteoarthritis industry? What are the key market trends impacting the growth of the Stem Cell Therapy for Osteoarthritis Market? What is the Stem Cell Therapy for Osteoarthritis Market challenges to market growth? What are the Stem Cell Therapy for Osteoarthritis Market opportunities and threats faced by the vendors in the global Stem Cell Therapy for Osteoarthritis Market?

Stem Cell Therapy for Osteoarthritis Market track and analyse competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, research and developments, with respect to the current market size and future prospective.

For Best Discount on purchasing this report, Visit https://dataintelo.com/ask-for-discount/?reportId=80747

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry.Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info Name Alex MathewsPhone +1 909 545 6473Email [emailprotected]Website https://dataintelo.comAddress 500 East E Street, Ontario, CA 91764, United States.

This post was originally published on Info Street Wire

More here:
Stem Cell Therapy for Osteoarthritis Market Report by Manufacturers, Regions, Type and Application Forecast 2019 2025 - Info Street Wire

Chinese scientist who claimed he genetically edited babies gets prison term – Los Angeles Times

A Chinese scientist who set off an ethical debate with claims that he had made the worlds first genetically edited babies was sentenced Monday to three years in prison because of his research, state media said.

He Jiankui, who was convicted of practicing medicine without a license, was also fined the equivalent of $430,000 by a court in the southern city of Shenzhen, Chinas official Xinhua News Agency reported. Two other researchers involved in the project received lesser sentences and fines.

The verdict said the three defendants had not obtained qualification as doctors, pursued fame and profits, deliberately violated Chinese regulations on scientific research and crossed an ethical line in both scientific research and medicine, according to Xinhua. It also said they had fabricated ethical review documents.

The court said the researchers were involved in the births of three gene-edited babies to two women, confirming reports of a third baby. It said all three pleaded guilty during the trial, which Xinhua reported was closed to the public because of privacy concerns.

He, the lead researcher, shocked the scientific world when he announced in November 2018 that he had altered the embryos of twin girls who had been born the same month. He described his work in exclusive interviews with the Associated Press.

The announcement sparked a global debate over the ethics of gene editing. He said he had used a tool called CRISPR to try to disable a gene that allows the AIDS virus to enter a cell, in a bid to give the girls the ability to resist the infection. The identity of the girls has not been released, and it isnt clear if the experiment succeeded.

The CRISPR tool has been tested elsewhere in adults to treat diseases, but many in the scientific community denounced Hes work as medically unnecessary and unethical, because any genetic changes could be passed down to future generations. The U.S. forbids editing embryos except for lab research.

He, who is known as JK, told the AP in 2018 that he felt a strong responsibility to make an example and that society would decide whether to allow the practice to go forward. He disappeared from public view shortly after he announced his research at a conference in Hong Kong 13 months ago, apparently detained by authorities, initially in an apartment in Shenzhen, a city in Guangdong province that borders Hong Kong.

It wasnt clear whether the three-year prison term includes any of the time he has already spent in Chinese custody.

A Chinese scientist said the sentence should have been harsher to deter others. Kehkooi Kee, a Tsinghua University researcher who conducts gene-editing research on stem cells, also said that He should be held responsible for any fallout from the experiment on the lives of the babies and their families.

Dr. William Hurlbut, a Stanford University bioethicist whose advice He sought for more than a year before his experiment, said he felt sorry for the scientist, his wife and two young daughters.

I warned him things could end this way, but it was just too late, Hurlbut wrote in an email to the AP and to the director of the U.S. National Institutes of Health, Dr. Francis Collins, and gene-editing pioneer Jennifer Doudna at UC Berkeley.

Sad story everyone lost in this (JK, his family, his colleagues, and his country), but the one gain is that the world is awakened to the seriousness of our advancing genetic technologies, Hurlbut wrote.

He studied in the U.S. before setting up a lab at the Southern University of Science and Technology of China in Shenzhen. The verdict accused him of colluding with Zhang Renli and Qin Jinzhou, who worked at medical institutes in the same province.

Zhang was sentenced to two years in prison and fined the equivalent of $143,145, Xinhua said. Qin received an 18-month prison sentence, but with a two-year reprieve, and the equivalent of a $71,573 fine.

Link:
Chinese scientist who claimed he genetically edited babies gets prison term - Los Angeles Times

Year in Review: Gene Therapy Technology and a Milestone 2019 for Medical Research – News18

In the summer, a mother in Nashville with a seemingly incurable genetic disorder finally found an end to her suffering -- by editing her genome. Victoria Gray's recovery from sickle cell disease, which had caused her painful seizures, came in a year of breakthroughs in one of the hottest areas of medical research -- gene therapy. "I have hoped for a cure since I was about 11," the 34-year-old told AFP in an email.

"Since I received the new cells, I have been able to enjoy more time with my family without worrying about pain or an out-of-the-blue emergency." Over several weeks, Gray's blood was drawn so doctors could get to the cause of her illness -- stem cells from her bone marrow that were making deformed red blood cells. The stem cells were sent to a Scottish laboratory, where their DNA was modified using Crispr/Cas9 -- pronounced "Crisper" -- a new tool informally known as molecular "scissors." The genetically edited cells were transfused back into Gray's veins and bone marrow. A month later, she was producing normal blood cells.

Medics warn that caution is necessary but, theoretically, she has been cured. "This is one patient. This is early results. We need to see how it works out in other patients," said her doctor, Haydar Frangoul, at the Sarah Cannon Research Institute in Nashville. "But these results are really exciting." In Germany, a 19-year-old woman was treated with a similar method for a different blood disease, beta thalassemia. She had previously needed 16 blood transfusions per year.

Nine months later, she is completely free of that burden. For decades, the DNA of living organisms such as corn and salmon has been modified. But Crispr, invented in 2012, made gene editing more widely accessible. It is much simpler than preceding technology, cheaper and easy to use in small labs. The technique has given new impetus to the perennial debate over the wisdom of humanity manipulating life itself. "It's all developing very quickly," said French geneticist Emmanuelle Charpentier, one of Crispr's inventors and the cofounder of Crispr Therapeutics, the biotech company conducting the clinical trials involving Gray and the German patient.

Cures

Crispr is the latest breakthrough in a year of great strides in gene therapy, a medical adventure started three decades ago, when the first TV telethons were raising money for children with muscular dystrophy. Scientists practising the technique insert a normal gene into cells containing a defective gene. It does the work the original could not -- such as making normal red blood cells, in Victoria's case, or making tumor-killing super white blood cells for a cancer patient. Crispr goes even further: instead of adding a gene, the tool edits the genome itself.

After decades of research and clinical trials on a genetic fix to genetic disorders, 2019 saw a historic milestone: approval to bring to market the first gene therapies for a neuromuscular disease in the US and a blood disease in the European Union. They join several other gene therapies -- bringing the total to eight -- approved in recent years to treat certain cancers and an inherited blindness. Serge Braun, the scientific director of the French Muscular Dystrophy Association, sees 2019 as a turning point that will lead to a medical revolution. "Twenty-five, 30 years, that's the time it had to take," he told AFP from Paris.

"It took a generation for gene therapy to become a reality. Now, it's only going to go faster." Just outside Washington, at the National Institutes of Health (NIH), researchers are also celebrating a "breakthrough period." "We have hit an inflection point," said Carrie Wolinetz, NIH's associate director for science policy.These therapies are exorbitantly expensive, however, costing up to $2 million -- meaning patients face grueling negotiations with their insurance companies. They also involve a complex regimen of procedures that are only available in wealthy countries.

Gray spent months in hospital getting blood drawn, undergoing chemotherapy, having edited stem cells reintroduced via transfusion -- and fighting a general infection. "You cannot do this in a community hospital close to home," said her doctor. However, the number of approved gene therapies will increase to about 40 by 2022, according to MIT researchers. They will mostly target cancers and diseases that affect muscles, the eyes and the nervous system.

Bioterrorism

Another problem with Crispr is that its relative simplicity has triggered the imaginations of rogue practitioners who don't necessarily share the medical ethics of Western medicine. Last year in China, scientist He Jiankui triggered an international scandal -- and his excommunication from the scientific community -- when he used Crispr to create what he called the first gene-edited humans. The biophysicist said he had altered the DNA of human embryos that became twin girls Lulu and Nana.

His goal was to create a mutation that would prevent the girls from contracting HIV, even though there was no specific reason to put them through the process. "That technology is not safe," said Kiran Musunuru, a genetics professor at the University of Pennsylvania, explaining that the Crispr "scissors" often cut next to the targeted gene, causing unexpected mutations. "It's very easy to do if you don't care about the consequences," Musunuru added. Despite the ethical pitfalls, restraint seems mainly to have prevailed so far.

The community is keeping a close eye on Russia, where biologist Denis Rebrikov has said he wants to use Crispr to help deaf parents have children without the disability. There is also the temptation to genetically edit entire animal species -- malaria-causing mosquitoes in Burkina Faso or mice hosting ticks that carry Lyme disease in the US. The researchers in charge of those projects are advancing carefully, however, fully aware of the unpredictability of chain reactions on the ecosystem.

Charpentier doesn't believe in the more dystopian scenarios predicted for gene therapy, including American "biohackers" injecting themselves with Crispr technology bought online. "Not everyone is a biologist or scientist," she said. And the possibility of military hijacking to create soldier-killing viruses or bacteria that would ravage enemies' crops? Charpentier thinks that technology generally tends to be used for the better. "I'm a bacteriologist -- we've been talking about bioterrorism for years," she said. "Nothing has ever happened."

Get the best of News18 delivered to your inbox - subscribe to News18 Daybreak. Follow News18.com on Twitter, Instagram, Facebook, Telegram, TikTok and on YouTube, and stay in the know with what's happening in the world around you in real time.

Excerpt from:
Year in Review: Gene Therapy Technology and a Milestone 2019 for Medical Research - News18

MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA | Antibodies | News Channels -…

DetailsCategory: AntibodiesPublished on Monday, 30 December 2019 14:42Hits: 67

PLANEGG/MUNICH, Germany I December 30, 2019 I MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tafasitamab, an anti-CD19 antibody, for the treatment of relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL). The BLA submission is based on the primary analysis data from the L-MIND trial of tafasitamab in combination with lenalidomide in patients with r/r DLBCL and the retrospective observational matched control cohort Re-MIND evaluating efficacy outcomes of r/r DLBCL patients who received lenalidomide monotherapy.

"The BLA submission marks a significant milestone in MorphoSys' history and demonstrates our dedication to address the high medical need in relapsed or refractory DLBCL," said Dr. Malte Peters, Chief Development Officer of MorphoSys. "If approved, tafasitamab and lenalidomide could become an alternative treatment option for patients with this serious disease."

The FDA has a 60-day filing review period to determine whether the BLA is complete and acceptable for filing. MorphoSys will communicate the agency's decision.

About L-MINDL-MIND is a single arm, open-label phase 2 study, investigating the combination of tafasitamab and lenalidomide in patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL) after up to two prior lines of therapy, including an anti-CD20 targeting therapy (e.g. rituximab), who are not eligible for high-dose chemotherapy and subsequent autologous stem cell transplantation. The study's primary endpoint is objective response rate (ORR). Secondary outcome measures include duration of response (DoR), progression-free survival (PFS) and overall survival (OS). In May 2019, the study reached its primary completion. Primary analysis data with a cut-off date of November 30, 2018 included 80 patients enrolled into the trial who had received tafasitamab and lenalidomide and had been followed-up as per protocol for at least one year. Efficacy results in this update were based on response rates assessed by an independent review committee for all 80 patients. Based on earlier reported interim data from L-MIND, in October 2017 the U.S. FDA granted Breakthrough Therapy Designation for tafasitamab plus lenalidomide in this patient population.

About Re-MINDRe-MIND, an observational retrospective study, was designed to isolate the contribution of tafasitamab in the combination with lenalidomide and to prove the combinatorial effect. The study compares real-world response data of patients with relapsed or refractory DLBCL who received lenalidomide monotherapy with the efficacy outcomes of the tafasitamab-lenalidomide combination, as investigated in MorphoSys's L-MIND trial. Re-MIND collected the efficacy data from 490 r/r DLBCL patients in the U.S. and EU. Qualification criteria for matching patients of both studies were pre-specified. As a result, 76 eligible Re-MIND patients were identified and matched 1:1 to 76 of 80 L-MIND patients based on important baseline characteristics. Objective response rates (ORR) were validated based on this subset of 76 patients in Re-MIND and L-MIND, respectively. The primary endpoint of Re-MIND has been met and shows a statistically significant superior best ORR of the tafasitamab/lenalidomide combination compared to lenalidomide monotherapy.

About tafasitamab (MOR208)Tafasitamab (MOR208) is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. Fc-modification of tafasitamab is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. Tafasitamab has been observed in preclinical models to induce direct apoptosis by binding to CD19, which is assumed to be involved in B cell receptor (BCR) signaling.MorphoSys is clinically investigating tafasitamab as a therapeutic option in B cell malignancies in a number of ongoing combination trials. An open-label phase 2 combination trial (L-MIND study) is investigating the safety and efficacy of tafasitamab in combination with lenalidomide in patients with relapsed/refractory DLBCL who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). Based on interim data from L-MIND, in October 2017 the U.S. FDA granted Breakthrough Therapy Designation for tafasitamab plus lenalidomide in this patient population. Re-MIND, the real-world data lenalidomide alone matched control cohort met its primary endpoint in October 2019, demonstrating clinical superiority of the tafasitamab/lenalidomide combination compared to lenalidomide alone. The ongoing phase 3 study B-MIND assesses the combination of tafasitamab and bendamustine versus rituximab and bendamustine in r/r DLBCL. In addition, tafasitamab is currently being investigated in patients with relapsed/refractory CLL/SLL after discontinuation of a prior Bruton tyrosine kinase (BTK) inhibitor therapy (e.g. ibrutinib) in combination with idelalisib or venetoclax.

About MorphoSysMorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 28 are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys's antibody technology to receive regulatory approval. The Company's most advanced proprietary product candidate, tafasitamab (MOR208), has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 405 employees. More information at https://www.morphosys.com.

SOURCE: Morphosys

Read the original:
MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA | Antibodies | News Channels -...

All the feels: From start to finish, a year of emotional stories – Golf Channel

No matter how packed with all that makes the game greata golf year might be and Id contend that theres never been a year that wasnt it wont stand out in history unless it has one extra special moment. And 2019 had that.

Golfs broad strokes rarely cut as wide a swath through culture as the Big 3 team sports, but Tiger Woods victory at the Masters was voted The Associated Presss top sports story of the year. Its importance may come to be considered greater than his 1997 Masters victory, or his U.S. Open wins at Pebble Beach in 2000 and Torrey Pines in 2008. And as a comeback from adversity, Woods first major victory in 11 years at least rivals and arguably surpasses not only Ben Hogans 1950 U.S. Open, but ANY sports comeback ever. It was extra special.

But so much else happened in 2019. What to make of the rest?

Well, lets start with Woods. Its easy to forget that a lot of things had to go just right on Sunday for Tiger to win at Augusta. And that as much as the place is considered his sweet spot, he hadnt won there since 2005. For me, the singular moment that meant more going forward was the Zozo Championship in November. Not because it became Woods record-tying 82nd career. And despite the tournament being a limited field, off-season event over a short golf course in a faraway land.

Was there any doubt? For our No. 1 Storyline of the Year, we look back on Tiger Woods' 15th major title at the Masters Tournament.

It was the WAY that Tiger played with a return to an ease and smoothness in his action that not only recalled much earlier days, but which promises repeatability and consistency. As well as on the right occasions dominance.

Next on the hit parade the education of Rory McIlroy. The four-time major winner added important elements to his game namely better putting and overall ball control to set the foundation for another sustained run of greatness in his 30s.

But it was also a year of searching. McIlroy came into 2019 reflective and open to new ideas. He said meditation, juggling and several self-help books had led him to decide that he would no longer allow my score to define who I am as a person. His consistency improved and he impressively won The Players in March. But McIlroy also had several flattish Sundays with chances to win, and the Masters where he continues to chase the career Grand Slam didnt go so well.

Prior to the U.S. Open, McIlroy roared to a seven-shot win in Canada. But he tied for ninth at Pebble Beach. Expectations were again high at Portrush, a short car ride from his boyhood home and where he had shot the course record of 61 at age 16. He opened The Open with a nervous 79 and missed the cut. The next week he got boat-raced by winner Brooks Koepka in a final Sunday pairing at the WGC-FedEx in Memphis.

It was again time to reassess.

After winning the FedExCup at East Lake, this time outplaying Koepka in the last group in what he would later call the highlight of his year, McIlroy revealed having committed to a harder and more self-aware competitive edge.

I think one of the biggest things is sometimes Ive tried to treat Sundays the same as a Thursday or Friday, and theyre not, said McIlroy, who would go on to win WGC-HSBC in Shanghai in November for his fourth victory of the year. Ive gone into them maybe a little too relaxed, but its not the same, and its about trying to get yourself in the right mindset. I guess thats the ultimate compliment I can give Brooks is that I wanted to be a little bit more like him.

McIlroy on Koepka rivalry: Feels good to take down No. 1

Speaking of Big Game Brooks, his ruthless march through the major championships since 2017 has been undervalued. In the last 30 years, only Woods, McIlroy and Nick Faldo have had such prolonged periods of excellence in the biggest events.

This year, Koepka showed true dominance in building a seven-stroke lead through three rounds in his victory at the PGA at Bethpage. That he bookended that performance with seconds at the Masters and at the U.S. Open got short shrift. And after he finished fourth at Portrush, when his putter uncharacteristically failed him (and he was being bothered by a torn patella tendon in his left knee that required stem cell treatment and from which he is still recovering), too many acted as though his reign had ended.

That impression was strengthened when McIlroy was chosen as PGA Tour Player of the Year by a vote of his peers. In the last couple of years, Koepka has used relatively small slights for fuel. But going into 2020 and turning 30 in May, he will be on a mission to strengthen his hold on world No. 1 and outdo McIlroy in the process. Koepka betrayed some saltiness in October by pointing out that, Ive been out here for what, five years. Rory hasnt won a major since Ive been on the PGA Tour. So I dont view it as a rivalry.

Sounds like a rivalry.

Although Jon Rahm, who enters 2020 at No. 3 in the world, is expected to intrude.

The 25-year-old Spaniard earns the description beast in the same way as team sport athletes who appear physically overwhelming. Along with his nine combined victories on the PGA and European tours, Rahm has also validated his combination of power and touch with a relentless consistency in his first 89 official worldwide professional starts, Rahm has 44 top-10s, only one less than Woods in his first 89. As he continues to mature and he got married just this month expect a calmer, more controlled Rahm to be even more dangerous.

In the womens game, Jin Young Ko was by far the best player of the year, winning two majors and two other events in only her second season on the LPGA tour. In a gracious acceptance speech for year-end honors at the tours awards banquet, the 24-year-old South Koreans accented, but precise English reflected the same discipline and exactitude that is so evident in her game. The current Rolex No. 1 knows thats been a precarious perch over the last decade in womens golf, and she seems determined to change the cycle. This is not the end, she told the gathering, but only the beginning.

Ok, thats the highest profile stuff. But there was also a pervasive theme that permeated 2019. In so many ways, it was an extraordinarily feel-good year.

Usually in these end-of-the-year assessments, what sticks with me most and reinforces my generally tragic sense of competitive golf are the deeply wounding, self-induced losses brought on by late implosions. You know, Phil Mickelson at Winged Foot, Adam Scott at Royal Lytham & St. Annes, and Jordan Spieth at the 2016 Masters with plenty of other examples to stuff into the hurt locker. But as I remember 2019, only two players caused such sadness, Francesco Molinari at the Masters and Lizette Salas at the Womens British Open. Molinari, the seemingly unflappable ball-striking machine led by two strokes on the 12th tee Sunday at the Masters before mishitting an 8-iron into Raes Creek, opening the door for Woods. Salas, who played the best golf of her life with a closing 65 at Woburn, missed a 5-foot birdie putt on the 72nd hole, and then watched Hinako Shibuno win it with a 20-footer.

Instead of a bevy of heartbreak, we got a full complement of Capra-esque moments.

Winning putt: Pettersen clinches the Solheim Cup for Europe

Suzann Pettersen, after making an 8-footer on the final green in the last match that spelled the difference between winning and losing the Solheim Cup, announced her retirement at age 38. One of the great walk-offs ever in professional sports. Pettersen said she reached the decision spontaneously with the thought, This is it. This is the peak.

Shane Lowry, as an underachiever scarred by a Sunday failure at the 2016 U.S. Open, shouldering the immense mental load before thousands of home fans in a land that hadnt held the Open Championship since 1951, and winning by six. The panorama on Portrushs 72nd hole, with fansrunning up the fairway behind Lowry, some waving Irish flags in the rain amid a constant roar, was one of pure cathartic release.

Shibuno winning the Womens British Open at Woburn in her first professional tournament outside Japan. A babe in the woods at 20, she was bolstered by innocence and a constant, infectious smile, even as she four-putted early in the final round. Shibunocaught fire and closed with a 31 on the final nine, her final putt rammed in with a blissful freedom, to become the second Japanese player to win a major championship.

The scene at the inaugural Augusta National Womans Amateur, where the image of women striding the hallowed grounds was a transformative moment for the game. The impressive brand of head-to-head power golf played by winner Jennifer Kupcho and runner-up Maria Fassi was the icing on the cake.

The effervescent Helen Alfreddson winning the second U.S. Senior Womens Open at Pine Needles, the most joyous, about time and appreciated championship in golf. Love of the game is never more palpable than among too-long-ignored 50-and-over LPGA veterans, and Alfreddsons passion and exuberance spoke for them all.

Cameron Champ won the Safeway Open in October while dedicating his play to his gravely ill African-American grandfather, Mack, who started him in the game. The 24-year-old bombers calm as he garnered his second victory was reminiscent of Ben Crenshaws march to the 1995 Masters after being a pallbearer at the funeral of his teacher, Harvey Penick, earlier that week.

In the most exciting finish of the year, Matthew Wolff he of the fascinatingly powerful swing and unofficial leader of the games latest youth movement in only his third pro start, won the 3M Championship with an eagle on the 72nd hole to beat Bryson DeChambeau, who had also eagled the last, by one.

Finally and excuse my darkness Koepka and Rahm saving big victories after blowing huge Sunday leads. For some reason, nothing makes me happier (or more accurately relieved) than seeing a player who has gone from the zone to full meltdown, and then reverse what suddenly looks like his or her inevitable and awful fate in the nick of time. Koepka dug to the very bottom of his deep reservoir of poise to do it at Bethpage after four straight bogeys on the final nine had him lose all but one of his seven-stroke lead. Rahm had a five shot lead with 10 to play at the DP World in Dubai, but it was all gone thanks especially to a couple of knuckleheaded three-putts from inside 25 feet when he reached the 72nd hole. Hell remember that birdie with a smile and a shudder for the rest of his life.

Adding additional poignancy to our main theme, it was also the year of journeymen each capable, but with a history of struggle at the highest level seizing the day.

There is a fine line between success and slump in professional golf. It took only one swing to send Brendon Todd over that line and years to make it back.

Brendan Todd ran away with this category, returning from nearly four years in the wilderness that included a stretch of missing 37 of 41 cuts, to win back-to-back at Bermuda and Mayakoba, and then nearly won again at the RSM. The 34-year-old, who won the Byron Nelson in 2014, came down with a nightmare dose of the swing yips (the lose-it-way-right strain) that by late-2018 had him on the verge of giving up pro golf and opening a pizza franchise. Instead, Todd got some help from swing coach and former player Bradley Hughes and pulled off one of the great turnarounds in golf history.

And consider this roll call of others who went through storybook lost-and-found cycles to convert a week of magic into first victories that take them into 2020 with transformed lives: Max Homa (Wells Fargo Championship), JT Poston (Wyndham Championship), Nate Lashley (Rocket Mortgage), Lanto Griffin (Houston Open), Tyler Duncan (RSM Classic), Adam Long (Desert Classic). Inspirations all.

And at the risk of belaboring the feel-good point, it seemed that just about every level of pro golf ended the year on a happy note.

At the PGA Tours finale at East Lake, McIlroy spread much joy in Ponte Vedra, with one fell swoop validating the wisdom of the Tours more compressed and earlier finishing schedule, getting the new staggered start scoring system at the Tour Championship off on the right foot, and winning in the final group in another showdown with Koepka.

The LPGAs season ended on a high note with Sei Young Kim making a 22-foot birdie putt on the last hole to win the richest first-place prize ever in the womens game $1.5 million at the CME Group Tour Championship. A new format had been questioned for seeming to put sheer money over an equitable reward for season-long performance, but Kims stature as a top player and the cliffhanger nature of her victory over Charley Hull made for a satisfying result.

The PGA Tour Champions season ended with a bang when Jeff Maggert holed out from 123 yards for eagle to win the Charles Schwab Cup Championship in sudden-death.

And at the last big event of the year, the Presidents Cup, Woods was fittingly triumphant as both captain and player. And, as he has done more with age, a strong display of emotion spread the joy.

So finally, did something happen that set the tone for all this happiness? Was there a beginning?

Amy Bockerstette, a 20-year-old golfer with Down syndrome, got to play the iconic 16th hole at the Waste Management Phoenix Open and made par with Gary Woodland watching.

To say there wasnt would be to underestimate the impact of Amy Bockerstette, a 20-year-old collegiate golfer and Special Olympics athlete with Down syndrome, who in January played the 16th hole with Gary Woodland at the pro-am of the Waste Management Phoenix Open. Ill admit it, tears fill my eyes each time I watch the 2-minute and 50-second video, which has reached double-digit million views.

Seeing the way Bockerstette, clearly thrilled to meet her playing partners, Woodland and Matt Kuchar, reveled so genuinely as the center of attention on golfs iconic stadium hole, and then stepped up, assertively telling herself, I got this, is irresistible. She hit a good tee shot, followed with a deft bunker shot, and then, again repeating her mantra out loud, drilled the 10-footer for par with Nicklausian poise.

One guess at the phrase Woodland told himself before pulling off the shot of the year a perfectly clipped 60-degree wedge off the 17th green at Pebble Beach that carried and spun to within 4 feet and a crucial par.

Said Woodland of Bockertette: Theres nobody that Ive seen be in the moment as much as she is.

In a particularly feel-good year, it might have been the most extra special moment of all.

View original post here:
All the feels: From start to finish, a year of emotional stories - Golf Channel

Michael Schumacher update: How is Michael Schumacher doing – six years on? – Express.co.uk

Speaking to Shes Mercedes magazine last month, she said: He is in the best of hands right now and we are doing everything we can to help him.

Try to understand that we follow Michaels desire to keep his health a secret.

You can be sure that he is in the very best of hands and that we are doing everything humanly possible to help him.

Please understand if we are following Michaels wishes and keeping such a sensitive subject as health, as it has always been, in privacy.

Michael Schumachers fans have honoured Corinnas request, as Reiner Ferling, chairman of the Kerpen fan club, said they would provide all kinds of support.

He said: Unfortunately, the time has come again, the sixth anniversary of Michaels accident is coming around.

Six years full of hope that Michael will one day go out in public again. We know that Michael is in good hands, that he gets love, security and confidence.

Michael can count himself lucky to have such a strong family behind him.

Visit link:
Michael Schumacher update: How is Michael Schumacher doing - six years on? - Express.co.uk

Brain tumor organoids may be key to time-sensitive treatments for glioblastomas – Science Codex

PHILADELPHIA --Lab-grown brain organoids developed from a patient's own glioblastoma, the most aggressive and common form of brain cancer, may hold the answers on how to best treat it. A new study in Cell from researchers at Penn Medicine showed how glioblastoma organoids could serve as effective models to rapidly test personalized treatment strategies.

Glioblastoma multiforme (GBM) remains the most difficult of all brain cancers to study and treat, largely because of tumor heterogeneity. Treatment approaches, like surgery, radiation and chemotherapy, along with newer personalized cellular therapies, have proven to slow tumor growth and keep patients disease-free for some periods of time; however, a cure remains elusive.

"While we've made important strides in glioblastoma research, preclinical and clinical challenges persist, keeping us from getting closer to more effective treatments," said senior author Hongjun Song, PhD, Perelman Professor of Neuroscience in the Perelman School of Medicine at the University of Pennsylvania. "One hurdle is the ability to recapitulate the tumor to not only better understand its complex characteristics, but also to determine what therapies post-surgery can fight it in a timelier manner."

Co-senior authors include Guo-li Ming, MD, PhD, Perelman Professor of Neuroscience, and Donald O'Rourke, MD, the John Templeton, Jr., MD Professor in Neurosurgery, and director of the GBM Translational Center of Excellence at Penn's Abramson Cancer Center.

Lab-grown brain organoids -- derived from human pluripotent stem cells or patient tissues and grown to a size no bigger than a pea -- can recapitulate important genetic composition, brain cell type heterogeneity, and architecture, for example. These models are allowing researchers to recreate key features of patients' diseased brains to help paint a clearer picture of their cancer, and allowing them to explore ways to best attack it.

What makes organoids so attractive in GBM is timing and the ability to maintain cell type and genetic heterogeneity. While existing in vitro models have added to researchers' understanding of the biological mechanisms underlying the cancer, they have limitations. Unlike other models, which need more time to exhibit gene expression and other histological features that more closely represent the tumor, brain tumor organoids developed by the research group grow into use much more rapidly. That's important because current treatment regimens are typically initiated one month following surgery, so having a road map sooner is more advantageous.

In the new study, the researchers removed fresh tumor specimens from 52 patients to "grow" corresponding tumor organoids in the lab. The overall success rate for generating glioblastoma organoids (GBOs) was 91.4 percent, with 66.7 percent of tumors expressing the IDH1 mutation, and 75 percent for recurrent tumors, within two weeks. These tumor glioblastoma organoids can also be biobanked and recovered later for analyses.

Genetic, histological, molecular analyses were also performed in 12 patients to establish that these new GBOs had largely retained features from the primary tumor in the patient.

Eight GBO samples were then successfully transplanted into adult mouse brains, which displayed rapid and aggressive infiltration of cancer cells and maintained key mutation expression up to three months later. Importantly, a major hallmark of GBM -- the infiltration of tumor cells into the surrounding brain tissue -- was observed in the mouse models.

To mimic post-surgery treatments, the researchers subjected GBOs to standard-of-care and targeted therapies, including drugs from clinical trials and chimeric antigen receptor T (CAR-T) cell immunotherapy. For each treatment, researchers showed that the organoid responses are different and effectiveness is correlated to their genetic mutations in patient tumors. This model opens the possibility for future clinical trials for personized treatment based on individual patient tumor responses to various different drugs.

Notably, the researchers observed a benefit in the organoids treated with CAR T therapies, which have been used in ongoing clinical trials to target the EGFRvIII mutation, a driver of the disease. In six GBOs, the researchers showed specific effect to patient GBOs with the EGFRvIII mutation with an expansion of CAR T cells and reduction in EGFRvIII expressing cells.

"These results highlight the potential for testing and treating glioblastomas with a personalized approach. The ultimate goal is to work towards a future where we can study a patient's organoid and test which CAR T cell is going to be the best against their tumor, in real time." O'Rourke said. "A shorter-term goal, given the heterogeneity of glioblastomas, is that in vitro testing of various therapeutic options may also help refine patient enrollment in clinical trials, by more accurately defining mutations and selecting the appropriate, available targeted therapies for each."

Here is the original post:
Brain tumor organoids may be key to time-sensitive treatments for glioblastomas - Science Codex